Meta AnalysisID 6689
消癌平注射液辅助铂类化疗治疗晚期非小细胞肺癌：一项系统评价和Meta分析
CRD42019136661
It is uncertain whether there is robust evidence on the efficacy and safety of Xiao-ai-ping injection as adjuvant therapy to platinum-based chemotherapy. Thus, we conducted a comprehensive systematic review on the effica
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6689
- Evidence Id
- 15247
- Core Evidence Id
- 15247
- Source Meta Analysis Id
- 6670
- Herb2 Meta Analysis Id
- HBMA006670
- Crd Id
- CRD42019136661
- Title
- Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
- Review Question
- It is uncertain whether there is robust evidence on the efficacy and safety of Xiao-ai-ping injection as adjuvant therapy to platinum-based chemotherapy. Thus, we conducted a comprehensive systematic review on the efficacy and safety of Xiao-ai-ping injection as an adjunctive therapy for advanced Non-small-cell-lung-cancer.
- Study Type Included
- Only clinical randomized controlled trials (RCTs) were eligible
- Condition Being Studied
- Lung cancer is a health burden in recent years, and it remains one of the leading causes of cancer related death worldwide, with approximately 1.8 million new lung cancer cases and 1.6 million deaths per year
- Participant
- The diagnosis of NSCLC had been verified by cytology or tissue biopsy. Furthermore, the patients had pathologically documented NSCLC of stage III or IV, according to the tumor-node-metastasis (TNM)-based staging of lung cancer.
- Animal
- Human Disease Modelled
- Intervention
- The patients received platinum-based chemotherapy with Xiao-ai-ping injection.
- Comparator Control
- The patients received platinum-based chemotherapy without Xiao-ai-ping injection.
- Main Outcome
- Objective tumor response (ORR), Quality of life, Measures of effect Objective tumor response measure is defined adding complete response (CR) and partial response (PR). Quality of life is reflected by KPS (KPS was considered as an indication for the quality of life in NSCLC patients after treatment . A 10-point change of KPS was regarded as improvement or deterioration of quality of life)
- Outcome Measure
- Additional Outcome
- Reduction in grade 3/4 myelosuppression, Reduction in grade 3/4 nausea and vomiting, Dysregulated liver and kidney function, diarrhea, constipation and fatigue, Immune function. Measures of effect reduction in grade 3/4 myelosuppression and, nausea and vomiting, other adverse side events including, dysregulated liver and kidney function, diarrhea, constipation and fatigue, and immune function including, the percentage of CD4+, CD8+, CD4+/CD8+, were regarded as secondary outcomes.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Carcinoma, Non-Small-Cell Lung; Humans; Injections; Lung Neoplasms; Lymphatic System; Platinum
- Contact
- Fanchao Feng [email protected]
- Organisational Affiliation
- Nanjing University of Chinese Medicine
- Funding Source
- This work was supported by the Project of Key Discipline for TCM Construction of Jiangsu Province, P.R. China [no. JS1302]
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2019-05-24
- Registration Date
- 2019-10-23
- Anticipated Start Date
- 2018-09-06
- Anticipated Completion Date
- 2019-07-31
- Title Cn
- 消癌平注射液辅助铂类化疗治疗晚期非小细胞肺癌：一项系统评价和Meta分析
- Title En
- Xiao-ai-ping injection adjunct with platinum-based chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
- Bilingual Status
- complete